Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363826 · ClinicalTrials.gov registry record · Phase 1
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
A Phase 1 study of Glioblastoma Multiforme of Brain and Glioma, Sarcomatous, sponsored by Photolitec.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05363826: Recruiting Phase 1 study of Glioblastoma Multiforme of Brain and Glioma, Sarcomatous, sponsored by Photolitec.
NCT05363826 is a Phase 1 study of Glioblastoma Multiforme of Brain and Glioma, Sarcomatous that is actively recruiting participants, run by Photolitec. The registered enrollment target is 30 participants, below the 156-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05363826, a Phase 1 study of Glioblastoma Multiforme of Brain and Glioma, Sarcomatous, is actively recruiting participants, sponsored by Photolitec.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is the first step in testing the hypothesis that adding Photobac® Photodynamic Therapy to surgical removal of a glioblastoma or gliosarcoma will be both safe and effective. Photodynamic Therapy (PDT) combines light and a photosensitizer. PDT has been used to treat a variety of cancers with varying degrees of success. For the past thirty years Photolitec has been working to develop a treatment for glioblastoma or gliosarcoma using light and a photosensitizer. Photolitec's scientists were looking for a photosensitizer that: 1. has no significant systemic toxicity apart from some temporary skin photosensitivity, 2. crosses the blood brain barrier, 3. accumulates to a high level in glioblastoma and minimally in the brain, 4. is activated by the wavelength of light that penetrates most deeply into the brain, 5. minimizes any temporary skin photosensitivity. Preliminary testing indicates the Photolitec team has achieved these five goals. Photolitec is now able to offer a clinical trial based on the results of this work.
Conditions Studied
Interventions
- COMBINATION_PRODUCT photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)
Study Locations (1)
New York
- Roswell Park Cancer - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT05363826 shows while recruiting
NCT05363826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 156-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Glioblastoma Multiforme of Brain appearing as the primary indexed condition, and to 1 intervention - of which photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®) is the first listed.
NCT05363826 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05363826 about?
NCT05363826 is a clinical study titled "Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®". This study is the first step in testing the hypothesis that adding Photobac® Photodynamic Therapy to surgical removal of a glioblastoma or gliosarcoma will be both safe and effective. Photodynamic Therapy (PDT) combines light and a photosensitizer. PDT has been used to treat a variety of cancers wi...
What is the current status of trial NCT05363826?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-04-11. Estimated completion is 2026-05.
What conditions does trial NCT05363826 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme of Brain, Glioma, Sarcomatous.
What interventions are being tested in trial NCT05363826?
The interventions under investigation include: photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05363826?
This trial is sponsored by Photolitec, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05363826 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme of Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05363826's enrollment target sits among peer trials
30 8th of 11 higher than 4 of 11 other Glioblastoma Multiforme of Brain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme of Brain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
RECRUITING · Phase 1
-
Trial of C134 in Patients With Recurrent GBM
ACTIVE NOT RECRUITING · Phase 1
-
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
RECRUITING
-
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
RECRUITING
-
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI